Altavant Sciences
Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, NC, developing treatments for interstitial lung disease through in-licensed and acquired pipeline assets (including Onspira Therapeutics).
- Company typePrivate
- Founded2018
- HeadquartersCary, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Altavant Sciences does
Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, North Carolina. The company focuses on developing treatments for interstitial lung disease, an area where the addressable market is projected to reach $3.09 billion by 2030 at an 8.4% CAGR. Altavant builds its pipeline through both internal development and acquisitions, most notably acquiring Onspira Therapeutics in January 2020 for an undisclosed amount to bring in respiratory and rare-disease assets.
The company operates with a lean team of 11-50 employees under a senior leadership structure typical of clinical-stage biotechs: Bill Symonds serves as CEO, Howard Lazarus as Chief Medical Officer, Lyn Baranowski as Chief Operating Officer, and Beth Anne Lang as Senior Vice President of Global Regulatory Affairs. This composition emphasizes clinical development execution and regulatory navigation rather than commercial-scale functions, consistent with a pre-commercial stage of development. Altavant is privately held, has not disclosed funding rounds in the provided data, and generates no commercial product revenue based on available information. Its business model is therefore dependent on capital markets and/or strategic partnerships to fund continued clinical advancement of its ILD pipeline.
Altavant Sciences firmographics
Firmographics- Name
- Altavant Sciences
- Website
- https://altavant.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Altavant Sciences is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Cary, NC, developing treatments for interstitial lung disease through in-licensed and acquired pipeline assets (including Onspira Therapeutics).
- Ownership category
- akta.pro rank
Altavant Sciences industry classification
Industry- Product category
- Biopharmaceuticals / Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industry
- Clinical Research & Trial Central Laboratories (HLAFAMAL)
Keywords
Where Altavant Sciences is headquartered
LocationHeadquarters
- HQ city
- Cary
- HQ country
- United States
- HQ region
- North America
Markets served
Altavant Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Altavant Sciences product offering
Product offeringCore offering
Altavant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for interstitial lung disease (ILD) and rare respiratory conditions. The company expanded its pipeline through the acquisition of Onspira Therapeutics on 2020-01-08, bringing in complementary drug development programs. It operates as a development-focused subsidiary within the Sumitomo Pharma group, targeting an ILD market projected to reach $3.09 billion by 2030.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical-stage ILD therapeutic pipeline Clinical-stage biopharmaceutical development programs targeting interstitial lung disease and rare respiratory conditions, acquired through the Onspira Therapeutics transaction and advanced under the Sumitomo Pharma group. Intended for onward commercialization or partnership with larger biopharma organizations.
Companies that use Altavant Sciences
Customer profileIdeal customer profiles1 record
Altavant Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Altavant Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Prometheus BiosciencesPrometheus Biosciences was acquired by Merck, mentioned in market context as a key development in the interstitial lung disease space to enhance pipeline capabilities.
Scale indicators1 record
Recent moves3 records
Expansion highlights3 records
Altavant Sciences competitors and assessment
Company assessmentDirect peers
- FibroGen: Biopharma with late-stage programs in IPF/ILD (pamrevlumab) and other fibrotic diseases; directly comparable therapeutic focus and clinical stage.
- Pliant Therapeutics: Clinical-stage biopharma developing therapies for idiopathic pulmonary fibrosis and other ILDs; directly comparable in indication, stage, and therapeutic modality.
- United Therapeutics: Specialty biopharma with pulmonary hypertension and ILD-relevant programs (tyvaso DPI for PH-ILD); comparable in rare respiratory disease focus and commercialization model.
- Galapagos NV: Developed ziritaxestat and other IPF/ILD candidates through clinical trials; directly comparable in ILD drug development activity and pipeline focus.
Emerging players
- Bellus Health: Clinical-stage biopharma developing therapeutics for refractory chronic cough and related respiratory conditions; comparable as a small respiratory-focused clinical developer.
- Roivant Sciences: Clinical-stage biopharma "Vant" platform developing multiple therapeutic candidates including respiratory assets; comparable as a small-focused clinical-stage entity with similar development philosophy.
- Blade Therapeutics: Clinical-stage company developing antifibrotic therapies for IPF and other fibrotic diseases; comparable as a smaller, focused ILD/fibrosis developer.
Broad incumbents
- Horizon Therapeutics (Amgen): Specialty/rare disease biopharma with respiratory inflammation programs (e.g., Actimmune for IPF); broader portfolio but overlapping in rare respiratory disease development.
- Boehringer Ingelheim: Established large-pharma with the approved ILD therapy nintedanib (Ofev); broader respiratory portfolio but directly defines the ILD competitive landscape Altavant must navigate.
Others
- Sumitomo Pharma America: U.S. subsidiary of Sumitomo Pharma with rare disease and respiratory programs referenced in the company data; relevant as a strategic/pharma ecosystem participant in the ILD space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
Altavant Sciences social profiles
Digital presenceAltavant Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altavant Sciences leadership team
Management profileNumber of profiles
Profiles4 records
Altavant Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altavant Sciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altavant Sciences
What does Altavant Sciences do?
Altavant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for interstitial lung disease (ILD) and rare respiratory conditions. The company expanded its pipeline through the acquisition of Onspira Therapeutics on 2020-01-08, bringing in complementary drug development programs. It operates as a development-focused subsidiary within the Sumitomo Pharma group, targeting an ILD market projected to reach $3.09 billion by 2030.
Is Altavant Sciences a public or private company?
Altavant Sciences is a private company. It is classified as corporate owned and is currently operating.
When was Altavant Sciences founded?
Altavant Sciences was founded in 2018. It employs 11 to 50 people.
Where is Altavant Sciences based?
Altavant Sciences is headquartered in Cary, United States, in the North America region.
Who are Altavant Sciences's main competitors?
Direct peers on record are FibroGen, Pliant Therapeutics, United Therapeutics and Galapagos NV. Emerging players are Bellus Health, Roivant Sciences and Blade Therapeutics. Broad incumbents are Horizon Therapeutics (Amgen) and Boehringer Ingelheim. Sumitomo Pharma America is listed as an others.
Does Altavant Sciences have an API?
No public API is recorded for Altavant Sciences.
What industry is Altavant Sciences in?
Altavant Sciences's product category is Biopharmaceuticals / Drug Development. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 541714 and its SIC code is 2834.